PATENT CLAIM ANALYSIS

Application Number: 15954457
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "094000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as osteoarthritis.

Claim (Index 8):
A method of treating osteoarthritis, comprising: 1) fasting a human being for at least one hour, wherein the human being is suffering from osteoarthritis, followed by 2) orally administering a dosage form comprising zoledronic acid to the human being, followed by 3) fasting the human being for at least one hour, wherein the patient is selected for having: 1) a bone marrow lesion and 2) OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, wherein the zoledronic acid is administered in a manner that results in a bioavailability of zoledronic acid that is about 2% to 3%.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15934785', '15897947', '15403073', '15697267', '15624428']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8336328329179998
- 35 USC 102 Novelty (BERT): 0.6421415648355674
- Combined Prediction Score: 0.8144837061097566
- Mean Citation Score: 667.2247199999998
- Max Citation Score: 701.7666
- Similarity Product: 590.6889224323869

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test